Real Answers to Real Questions

Tackle Real-World, Practical Questions that Endocrinologists and Endocrinology-focused HCPs Face Every Day

Once-weekly basal insulin regimens are poised to enter the treatment armamentarium for diabetes management. Gaps in understanding the unique molecular design contribute to therapeutic inertia and delayed implementation of a more convenient, flexible, and potentially safer alternative to daily insulin regimens for patients with T2D.

This event is designed for US-based endocrinologists and endocrinology-focused NPs and PAs involved in the management of patients with type 2 diabetes (T2D). Participants will gain actionable insights from expert faculty, who will explore:

  • Differentiate emerging once-weekly basal insulins from traditional once-daily formulations based on molecular structure, mechanism of action, and pharmacokinetic/pharmacodynamic properties
  • Interpret the efficacy and safety data of once-weekly basal insulins in late-stage development
  • Develop a comprehensive, individualized evidence-based treatment plan for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration

Reserve Your Seat Today & Earn up to 1.0 AMA, ABIM MOC, AAPA, ANCC, IPCE credit/contact hour for FREE!

 In-Person Registration

Name
Profession
What is your primary specialty?

Dates & Locations:

 

10/6/26 – Chicago, IL | 5:30 – 7:00 PM CT

Maggiano’s Little Italy

516 N Clark St., Chicago, IL 60654

11/18/26 – Minneapolis, MN | 5:30 – 7:00 PM CT

CRAVE Food & Drink LaSalle Plaza-Minneapolis

825 Hennepin Ave, Minneapolis, MN 55402

This activity is designed for Endocrinologists and endocrinology-focused NPs and PAs who care for patients with T2D in the United States. 

  • Introduction
  • Assessing The Current Limitations of Basal Insulin and Emerging Role of Novel Therapies
  • Evaluating Efficacy and Safety of Weekly Basal Insulins
  • Developing and Implementing Comprehensive Treatment Plans
  • Conclusion

After completing this activity, the participant should be better able to: 

  • Differentiate emerging once-weekly basal insulins from traditional once-daily formulations based on molecular structure, mechanism of action, and pharmacokinetic/pharmacodynamic properties

  • Interpret the efficacy and safety data of once-weekly basal insulins in late-stage development

  • Develop a comprehensive, individualized evidence-based treatment plan for patients with type 2 diabetes who require basal insulin that incorporates best practices for initiation, dosing, and titration

This activity is provided by MLI

 
Accreditation, Support and Credit 

Joint Accreditation with Commendation Logo

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

  

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

MOC Statement 

ABIM MOC Part II Credit | WashU Continuing Medical Education | Washington University in St. LouisSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS). 

For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit. 

 
PA 

Medical Learning Institute Inc has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation. 

 
Nursing Continuing Professional Development 

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour(s) in the area of pharmacology. 

Interprofessional Continuing Education (IPCE) Statement 

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. 

 
MIPS 

Completion of this accredited CE activity will meet the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). 

Support Statement

This activity is supported by an educational grant from Lilly.

Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Chair/Planner/Presenter
Julio Rosenstock, MD, has a financial interest/relationship or affiliation in the form of: 
Consultant/Advisor: Amgen, Applied Therapeutics, Arrowhead, Biomea Fusion, Boehringer Ingelheim, Corcept, Eccogene, Hanmi, i2O Therapeutics, Lilly, Novo Nordisk, Regeneron, Roche, Sanofi, Structure Therapeutics, Terns

Speaker/Member of Speaker’s Bureau: Received honoraria for lectures: Lilly, Novo Nordisk, Sanofi

Research Funding/Support: All have ended: Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, Boehringer Ingelheim, Corcept, Corxel, Hanmi, Lilly, Merck, Novo Nordisk, Pfizer, Regeneron, Roche, Regor, Sanofi, Structure Therapeutics, Terns

Planner/Presenter
Marc-André Cornier, MD, has a financial interest/relationship or affiliation in the form of:

Consultant/Advisor: AstraZeneca, Biophytis, Bonus Health, Enveda, Keros, Lilly, Novo Nordisk, Rivus, Wave, ZyVersa
Research Funding/Support (to institution): Cleery, Ionis, Kaneka, Novartis
 

Planner/Presenter

Jennifer Green, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Bayer, Boehringer Ingelheim, Corcept, Idorsia, Lilly, Merck, Mineralys, Novo Nordisk, Sparrow, Valo, Vertex, Zealand
Research Funding (to institution): Boehringer Ingelheim, COUR, GentiBio, Merck, Metsera

Patient

Ronnie Williams has no relevant financial relationships with ineligible companies to disclose for this educational activity.

 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, does not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.

About This Activity

Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.

This activity is supported by an educational grant from Lilly.

Scroll to Top